Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
| Image |  |
|---|---|
| Description | scientific article published on 01 June 2017 |
| Author/s |
author: Jordi Bruix |
| Publication date | June 1, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |